In summary, the data presented in this manuscript indicate that substitution of the MeV envelope glycoproteins by CD46-targeted CDV envelope glycoproteins is an alternative strategy to circumvent the inhibition of MeV-immune serum and achieve oncolysis in multiple myeloma and ovarian cancer models. This evidence concerns the gene ERVW-1 and ovarian cancer.